Cripto-1 Promotes Epithelial-mesenchymal Transition in Prostate Cancer Via Wnt/β-catenin Signaling
Authors
Affiliations
The Cripto-1 (CR-1) derived EGF-CFC family was overexpressed in tumor development enhancing proliferation, epithelial-mesenchymal transition (EMT) and migration of tumor cells. However, correlation between CR-1 and prostate cancer (PCa) remains still unclear. In the present study, we proved that CR-1 was expressed in PCa and its function was in the progression of PCa. Compared with benign prostatic hyperplasia (BPH) tissues, we confirmed that PCa tissues had high expression of CR-1 by immunohistochemistry and statistical data showed that CR-1 promoted properties of EMT in PCa tissues, including the downregulation of the cell adhesion molecules β-catenin (membrane) and E-cadherin while upregulating transcription factors β-catenin. Overexpression of CR-1 had close relationship with PSA, Gleason, clinical staging and lymph node metastasis in PCa patients. Then, we found that PC-3 cells transfected with CR-1-shRNA inhibited EMT using RT-PCR, RT-qPCR, western blotting and immunofluorescence. Also, we evaluated cell invasive ability in vitro by transwell and wound-healing assay. Our data showed that transfected CR-1-shRNA altered EMT including β-catenin, E-cadherin, c-myc, GSK-3, p-GSK and Wnt/β-catenin pathway in PC-3. It also suppressed PC-3 cell migration. Additionally, our results displayed that Licl had antitumor activity against PC-3 through the inhibition of Wnt/β-catenin pathway. Inhibition of cell viability was dose-time dependent. The present study proved that CR-1 regulates EMT of PCa by Wnt/β-catenin pathway. Hence, CR-1 may provide a new biological marker, and possibly contributes to clinical treatment against PCa.
Aria H, Azizi M, Nazem S, Mansoori B, Darbeheshti F, Niazmand A Heliyon. 2024; 10(15):e35208.
PMID: 39170516 PMC: 11337742. DOI: 10.1016/j.heliyon.2024.e35208.
Varisli L, Tolan V, Cen J, Vlahopoulos S, Cen O Oncol Res. 2023; 30(3):137-155.
PMID: 37305018 PMC: 10208071. DOI: 10.32604/or.2022.026074.
Nascente E, Amorim R, Fonseca-Alves C, de Moura V Cancers (Basel). 2022; 14(11).
PMID: 35681707 PMC: 9179314. DOI: 10.3390/cancers14112727.
Wnt/β-catenin signal transduction pathway in prostate cancer and associated drug resistance.
Wang C, Chen Q, Xu H Discov Oncol. 2022; 12(1):40.
PMID: 35201496 PMC: 8777554. DOI: 10.1007/s12672-021-00433-6.
Whence CRIPTO: The Reemergence of an Oncofetal Factor in 'Wounds' That Fail to Heal.
Freeman D, Rodrigues Sousa E, Karkampouna S, Zoni E, Gray P, Salomon D Int J Mol Sci. 2021; 22(18).
PMID: 34576327 PMC: 8472190. DOI: 10.3390/ijms221810164.